NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,578.30 +102.38 (+0.55%) CRUDE OIL
78.82 +0.34 (+0.43%) GOLD FUTURES
2,334.70 +3.50 (+0.15%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,404.45 -512.99 (-1.01%)
Idorsia Ltd (IDIA.SW)
| Previous close | 2.0120 |
| Open | 2.0120 |
| Bid | 0.0000 x 0 |
| Ask | 2.0200 x 0 |
| Day's range | 1.9000 - 2.0500 |
| 52-week range | 1.2940 - 9.7500 |
| Volume | |
| Avg. volume | 1,177,969 |
| Market cap | 349.433M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1100 |
| Earnings date | 21 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Jun 2017 |
| 1y target est | 1.74 |
Globe NewswireBondholders approve amended terms of the 2024 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the bondholders and will become binding and effective upon approval by the higher cantonal composition authority. Allschwil, Switzerland – May 6, 2024Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of a bondholder meeting held at 17:30 CEST on May 6, 2024. The bondholder meeting for holders
GlobeNewswireIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder meeting will take place on May 6, 2024, in order to vote on the proposals published on April 23, 2024. Allschwil, Switzerland – May 1, 2024Idorsia Ltd (SIX: IDIA) today announced that in relation to the bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN:
- Globe Newswire
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.A CHMP positive opinion is one of the final steps before marketing authorization can be granted by the European Commission – a final decision is expect
